TRANSFORMATIVE PLATFORM TECHNOLOGY
Upgrading Biologics with Spatial Precision Activity
Our proprietary tissue-activable platform is designed to activate biologics selectively at sites of disease, unlocking a new era of precision immunotherapy. Unlike traditional systemic biologics, our approach enables localized engagement of immune targets—maximizing therapeutic benefit, minimizing toxicity, and dramatically improving safety.
This modular and scalable platform can enhance entirely new biologics or upgrade existing ones—converting systemically limited molecules into best-in-class, organ-activated therapeutics. Our technology expands the boundaries of druggable biology and enables the development of transformative therapies once considered too risky or too toxic.
A scalable platform unlocking organ-targeted activity across assets and indications.
This approach applies across a wide range of therapeutic targets and disease indications, offering an adaptable toolkit to treat complex, tissue-specific autoimmune and inflammatory conditions. It enables disease-selective targeting in areas such as:
- Pancreas – Type 1 Diabetes (T1D)
- Gut – Inflammatory Bowel Disease (IBD)
- Joints – Rheumatoid Arthritis (RA)
- Liver – Primary Biliary Cholangitis (PBC)
- Brain – Multiple Sclerosis (MS)
- Kidney – Lupus Nephritis
By tailoring activation to these tissues, a single biologic—or an entire portfolio—can be fine-tuned to address multiple diseases across diverse indications. This unlocks powerful new opportunities to:
- Achieve first-in-class potential for previously limited biologics
- Expand indication breadth for novel immune-modulating therapies
- De-risk development with localized, safer immune engagement
TregShield Bio is pioneering the future of precision medicine—delivering biologics that activate exactly where they’re needed and transforming the treatment landscape for immune and inflammatory diseases.